Carl Zeiss Meditec Reports Stable Revenue Adjusted for Currency Fluctuations

Carl Zeiss Meditec AG announced stable revenue development on a currency-adjusted basis for the first nine months of the 2025/26 fiscal year, achieving €1,553.7 million in revenue, a slight decrease from the prior year's €1,600.1 million. However, the adjusted EBITA margin fell to 8.0% compared to last year's 11.1%, attributed to negative currency effects and lower consumables sales.

The company's Ophthalmology unit experienced a revenue decline of -4.8%, primarily due to reduced sales in China. Conversely, the Microsurgery unit saw a 3.8% revenue increase, bolstered by strong neurosurgical microscope deliveries. Regionally, EMEA showed 5.4% growth, while the Americas and APAC faced challenges due to weak market conditions.

Carl Zeiss Meditec remains focused on improving profitability and efficiency, with an earnings outlook of €2.15bn to €2.20bn for the fiscal year. The company is exploring ways to optimize its global manufacturing and streamline certain business segments.